These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33641009)

  • 1. Heterogeneity in α-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia.
    Sokratian A; Ziaee J; Kelly K; Chang A; Bryant N; Wang S; Xu E; Li JY; Wang SH; Ervin J; Swain SM; Liddle RA; West AB
    Acta Neuropathol; 2021 Apr; 141(4):547-564. PubMed ID: 33641009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
    Bargar C; Wang W; Gunzler SA; LeFevre A; Wang Z; Lerner AJ; Singh N; Tatsuoka C; Appleby B; Zhu X; Xu R; Haroutunian V; Zou WQ; Ma J; Chen SG
    Acta Neuropathol Commun; 2021 Apr; 9(1):62. PubMed ID: 33827706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
    Manne S; Kondru N; Hepker M; Jin H; Anantharam V; Lewis M; Huang X; Kanthasamy A; Kanthasamy AG
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):423-435. PubMed ID: 30706414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC.
    Sano K; Atarashi R; Satoh K; Ishibashi D; Nakagaki T; Iwasaki Y; Yoshida M; Murayama S; Mishima K; Nishida N
    Mol Neurobiol; 2018 May; 55(5):3916-3930. PubMed ID: 28550528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies.
    Rossi M; Candelise N; Baiardi S; Capellari S; Giannini G; Orrù CD; Antelmi E; Mammana A; Hughson AG; Calandra-Buonaura G; Ladogana A; Plazzi G; Cortelli P; Caughey B; Parchi P
    Acta Neuropathol; 2020 Jul; 140(1):49-62. PubMed ID: 32342188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
    Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
    Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
    Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
    Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
    Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
    Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
    Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.
    Kramer ML; Schulz-Schaeffer WJ
    J Neurosci; 2007 Feb; 27(6):1405-10. PubMed ID: 17287515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.
    Crews L; Spencer B; Desplats P; Patrick C; Paulino A; Rockenstein E; Hansen L; Adame A; Galasko D; Masliah E
    PLoS One; 2010 Feb; 5(2):e9313. PubMed ID: 20174468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of synuclein aggregation in Lewy body disease.
    Mukaetova-Ladinska EB; McKeith IG
    Mech Ageing Dev; 2006 Feb; 127(2):188-202. PubMed ID: 16297436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Real-time Quaking-induced Conversion Analysis of Prion-like Seeding Activity of Pathological α-Synuclein].
    Sano K
    Yakugaku Zasshi; 2019; 139(7):999-1005. PubMed ID: 31257259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
    Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Manne S; Kondru N; Jin H; Anantharam V; Huang X; Kanthasamy A; Kanthasamy AG
    Mov Disord; 2020 Feb; 35(2):268-278. PubMed ID: 31758740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
    Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
    Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein aggregates are excluded from calbindin-D28k-positive neurons in dementia with Lewy bodies and a unilateral rotenone mouse model.
    Rcom-H'cheo-Gauthier AN; Davis A; Meedeniya ACB; Pountney DL
    Mol Cell Neurosci; 2016 Dec; 77():65-75. PubMed ID: 27746320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential insular cortex subregional vulnerability to α-synuclein pathology in Parkinson's disease and dementia with Lewy bodies.
    Fathy YY; Jonker AJ; Oudejans E; de Jong FJJ; van Dam AW; Rozemuller AJM; van de Berg WDJ
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):262-277. PubMed ID: 29797340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB.
    Yan R; Zhang J; Park HJ; Park ES; Oh S; Zheng H; Junn E; Voronkov M; Stock JB; Mouradian MM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E12053-E12062. PubMed ID: 30509990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.